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Abstract 50 
The interaction between the immune system and the nervous system has been at the centre of 51 
multiple research studies in recent years. While the role played by cytokines as neuronal 52 
mediators is no longer contested, the mechanisms by which cytokines modulate pain 53 
processing remain to be elucidated. In this study, we have analysed the involvement of 54 
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in nociceptor activation in 55 
male and female mice. Previous studies have suggested GM-CSF might directly activate 56 
neurons. However, here we established the absence of a functional GM-CSF receptor in 57 
murine nociceptors, and suggest an indirect mechanism of action, via immune cells.  We 58 
report that GM-CSF applied directly to magnetically purified nociceptors does not induce any 59 
transcriptional changes in nociceptive genes. In contrast, conditioned medium from GM-60 
CSF-treated murine macrophages was able to drive nociceptor transcription. We also found 61 
that conditioned medium from nociceptors treated with the well-established pain mediator, 62 
Nerve Growth Factor (NGF), could also modify macrophage gene transcription, providing 63 
further evidence for a bidirectional crosstalk. 64 
Significance Statement 65 
The interaction of the immune system and the nervous system is known to play an important 66 
role in the development and maintenance of chronic pain disorders. Elucidating the 67 
mechanisms of these interactions is an important step towards understanding, and therefore 68 
treating, chronic pain disorders. This study provides evidence for a two-way cross talk 69 
between macrophages and nociceptors in the peripheral nervous system which may 70 
contribute to the sensitization of nociceptors by cytokines in pain development. 71 
 72 
 73 
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1. INTRODUCTION 74 
Chronic pain is a debilitating condition affecting large numbers of people (Phillips, 2009), 75 
with the prevalence in Europe estimated to be around 20% (Breivik et al., 2006). More 76 
surprising perhaps is that more than 50% of those suffering do not respond or get effective 77 
relief with current treatments (Nicol et al., 2018). Over the last decade, considerable advances 78 
have been made towards understanding the neuro-biological mechanisms underlying chronic 79 
pain, with several promising trials of new classes of drug (Ford, 2012; Brown et al., 2012; 80 
Schwertner et al., 2013).   81 
Substantial evidence has been presented to suggest that the interaction between neurons and 82 
immune cells can result in pain-related conditions stemming from the activation of 83 
nociceptors by immune system mediators (Marchand et al., 2005; Hore and Denk, 2019; 84 
Cook et al., 2018). Cytokines are also potent neuromodulators that are capable of activation 85 
and sensitization of nociceptors (Scholz and Woolf, 2007; Moalem and Tracey, 2006). One 86 
such mediator that we have chosen to investigate in this study is granulocyte-macrophage 87 
colony stimulating factor (GM-CSF).  88 
GM-CSF has been shown to act as a pro-inflammatory cytokine (Hamilton, 2008). GM-CSF 89 
can enhance antigen presentation and drive macrophages into a proinflammatory phenotype 90 
that produces inflammatory cytokines such as TNF, IL-6, IL-1β and CCL17 (Cook et al., 91 
2004; Fleetwood et al., 2007; Metcalf, 2008; Achuthan et al., 2016; Hamilton, 2008; Wicks 92 
and Roberts, 2016). GM-CSF signalling requires the presence of the GM-CSF receptor 93 
(CSF2R), a heterodimer made up of a low-affinity ligand binding α chain (CSF2Rα) and the 94 
signal transducing β chain (CSF2Rβ) in a ternary complex (Hamilton, 2008; Hansen et al., 95 
2008; Broughton et al., 2016). Down-stream signalling of GM-CSF involves the Ras/MAPK 96 
pathway as well as the JAK/STAT pathway (Hansen et al, 2008; Broughton et al., 2016). 97 
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Within the central nervous system, GM-CSF has been shown to play a neuro-inflammatory 98 
role by activating microglia (Parajuli et al., 2012; Nicol et al., 2018). The expression of GM-99 
CSFR has also been shown to be increased in infiltrating macrophages and in microglia-like 100 
cells in human spinal cord of Multiple Sclerosis patients (Donatien et al., 2018). Inhibition of 101 
GM-CSF signalling was found to attenuate arthritic pain (Cook et al., 2012). Additionally, 102 
silencing GM-CSF and the gene for its receptor resulted in analgesic effects in models of 103 
bone cancer and inflammatory pain (Schweizerhof et al., 2009; Cook et al., 2013). Functional 104 
studies have shown that injection of GM-CSF into the paw of laboratory animals produces 105 
pain-related behaviour (Acthuthan et al., 2016; Schweizerhof et al., 2009).  106 
However, the pathways and mechanisms behind GM-CSF mediated pain remain elusive 107 
(Wicks and Roberts, 2016). There have been claims that the receptor for GM-CSF is 108 
expressed in the peripheral nervous system, suggesting that GM-CSF could directly activate 109 
nociceptors and thereby drive pain and hyperalgesia (Schweizerhof et al., 2009; Bali et al., 110 
2013). However, multiple recent high throughput RNA sequencing studies suggest that 111 
neurons in the dorsal root ganglion (DRG) express the CSF2Rα transcript at very low levels 112 
but do not express any CSF2Rβ (Thakur et al, 2014; Lopes et al., 2017; Flegel et al., 2015; 113 
Zeisel et al., 2018). Since both receptor subunits are needed for GM-CSF signalling, these 114 
data sets suggest that any effect of GM-CSF on neurons would have to be indirect i.e. via 115 
another cell type. Many immune cells found in neuronal tissues do express appropriate 116 
receptors. Many studies of GM-CSF have to date studied systems containing multiple cell 117 
types, making it difficult to identify direct versus indirect effects.   118 
This study addresses this discrepancy and seeks to elucidate the mechanism behind the 119 
activation of nociceptors by GM-CSF. It demonstrates that GM-CSF can exert an indirect 120 
effect on nociceptors via macrophages. We show that pain-related genes are transcriptionally 121 
upregulated by conditioned media from bone marrow-derived macrophages (BMDMs) 122 
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treated in vitro with GM-CSF. Hence, while GM-CSF may be incapable of directly activating 123 
nociceptors, it can do so indirectly, and contribute to the algesic effects of GM-CSF. 124 
 125 
2. METHODS 126 
Animals 127 
For most experiments, adult female C57Bl/6J mice 6-8 weeks of age, weighing around 20-128 
25g were ordered from Envigo, UK. The animals were housed with a 12-hour light/dark cycle 129 
with lights on between 7.00 a.m. and 7.00p.m. and unrestricted access to food and water. 130 
Animals were housed in groups of 4-8 and cared for in accordance to the United Kingdom 131 
Animals Scientific Procedures Act (1986).  132 
In some experiments, adult male and female C57Bl/6J mice from the Walter and Eliza Hall 133 
Institute, Parkville, Australia) were used. Nav1.8-cre Csf2rb
fl/fl
 mice were generated by 134 
crossing the Csf2rb
fl/fl
 mouse (Croxford et al., 2015) with the Nav1.8-cre mouse (gift from JN 135 
Wood, London) (described in Stirling et al., 2005), i.e. mice with any GM-CSFR expression 136 
deleted in Nav1.8
+
 neurons. Where appropriate, experiments were approved by The 137 
University of Melbourne Animal Ethics Committee. 138 
Isolation of DRGs and their dissociation by magnetic separation 139 
Adult female C57Bl/6J mice were terminally euthanized with an overdose of pentobarbital 140 
and death confirmed by decapitation. The DRG were taken from all vertebral levels as 141 
previously described (Malin et al., 2007). DRG were washed in F12 medium and then 142 
dissociated by enzymatic digestion, followed by gentle mechanical dissociation (Thakur et 143 
al., 2014). The single cell suspension was exposed to a biotinylated nonneuronal antibody 144 
cocktail (Miltenyi MACS Neuron Isolation Kit), followed by antibiotin microbeads (Miltenyi 145 
MACS Neuron Isolation Kit). Cells were then run through a LD exclusion column and placed 146 
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in a QuadroMACS separator (Miltenyi Biotech) so that only neuronal cells were eluted 147 
(>95% pure neuronal cells generated). Neurons were then plated on Matrigel-coated 148 
coverslips and cultured for 48 hours (5% CO2, 95% O2, at 37°C) in medium with different 149 
stimuli as discussed below. For the initial set of experiments, MACS-sorted nociceptor 150 
cultures were prepared in parallel to traditional whole DRG cultures. These were treated for 151 
48 hours with either mouse GM-CSF (2µg/ml, Peprotech) or, as a positive control, mouse 152 
2.5S NGF (10ng/ml, Alomone labs).  153 
Bone marrow-derived macrophage isolation and cell culture. 154 
Adult female C57Bl/6J mice were terminally euthanized with pentobarbital and death 155 
confirmed by decapitation. The lower body was sterilized with 70% ethanol. The skin, 156 
muscles and fat surrounding femur, tibia and fibula were removed, and the bones collected in 157 
cold DMEM. The bones were flushed with 5–10 ml of cold PBS and the cells collected, 158 
resuspended and plated in DMEM containing 10% FBS, 1% penicillin–streptomycin (Sigma) 159 
and macrophage-colony stimulating factor (M-CSF, CSF-1) (Peprotech). Cultures were 160 
maintained for 1 week at 37°C (5% CO2/95% O2). Once confluent, cells were incubated with 161 
non-enzymatic cell dissociation buffer (Millipore) at 37°C for 10 min, scraped carefully and 162 
replated at a density of 30,000-50,000 cells per well in DMEM containing M-CSF. Twenty-163 
four hours later, the medium was replaced with M-CSF-free medium and cells were treated 164 
with either GM-CSF (2µg/ml) or LPS (100ng/ml) for 48 hours.  165 
Cross stimulation of nociceptor and BMDM cultures 166 
To look for indirect effects of mediators on pure nociceptors and BMDMs, MACS-sorted 167 
neurons and BMDMs were cultured for 48 hours with either media alone, GM-CSF or, as a 168 
positive control, NGF (for neurons) or LPS (for BMDMs). 48 hours later, fresh cultures of 169 
MACS-sorted neurons and BMDMs were plated, as described above. Supernatants from the 170 
neurons treated for 48 hours were added to the fresh BMDM cultures, and similarly 171 
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supernatants from the BMDMs treated for 48 hours were added to the fresh neuron cultures. 172 
Supernatants were centrifuged to remove any cells and then 1ml was added to the respective 173 
wells. These were further cultured for 24 hours, following which cells were taken for RNA 174 
extraction and gene expression analysis.  175 
RNA extraction and Taqman qPCR array cards 176 
In each of the experiments, cells were lysed and RNA was extracted from cultured whole 177 
DRG and MACS-sorted DRG samples using the RNeasy microkit (Qiagen) following the 178 
manufacturer’s protocol with some minor modifications. RNA integrity was assessed on the 179 
Agilent 2100 Bioanalyzer Pico Chip (Agilent, Santa Clara, CA). The RNA integrity number 180 
(RIN) for each of the samples used was >8. Samples with a RIN of <8 were not used for 181 
qPCR analysis. Following RNA extraction, the samples were amplified and reverse 182 
transcribed using the Repli-g WTA single cell amplification kit (Qiagen). The cDNA was 183 
used for gene expression analysis by using the Taqman custom-made microfluidic array cards 184 
(Thermofisher). These custom-made cards were designed in-house and contained primers and 185 
probes to detect 45 test genes as well as three housekeeping genes for reference (18S, 186 
GAPDH and Ywhaz (B2M in macrophage card)). Three types of cards were used in this 187 
study. The first card, used to look for differences between whole DRG and MACS-sorted 188 
samples, contained probe sets for a mixture of neuronal and non-neuronal genes known to be 189 
present in the DRG that can be activated by NGF and other mediators. These include genes 190 
such as TRPVI and TRPA1, ion-channels widely expressed on neuronal cells known to be 191 
involved in nociception (Caterina and Julius, 2001; Bevan, Quallo and Andersson, 2014; 192 
Huang et al., 2017). In addition, the array card contained probe sets for some cytokine and 193 
chemokine genes. The second card contained probe sets for genes that are known to be 194 
specifically involved in axotomy and pain-related behaviour. These included neuropeptides, 195 
such as Galanin and Neuropeptide Y, known for their role in nociception (Kerr et al., 2000; 196 
Brothers and Wahlestedt, 2010), proteins such as Annexin 1 and ADAM8 known for their 197 
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role in modulating inflammatory pain (Chen, Lv and Pei, 2014; Schlomann et al., 2000) in 198 
addition to other markers associated with pain such as CSF-1, BDNF and NGF. Finally, the 199 
third card contained probe sets for genes that are present in macrophages. They include 200 
canonical inflammatory mediators such as IL6, TNF and CCL17 (Laskin, 2009). The 201 
transcripts measured by each card are given in Table 1. 202 
Each cDNA sample was quantified using a Qubit BR ssDNA assay kit and diluted in PCR 203 
grade water to a final concentration of 6ng/µl. This was added to Taqman Universal 2x 204 
Master mix (Thermofisher) to achieve a final volume of 100 µl. TaqMan array cards were run 205 
on a 7900HT Fast Real-Time PCR system (Applied Biosystems) and gene expression 206 
calculated using the ddCT method (normalizing each sample to the average of the 207 
three housekeeping genes and then to their respective internal controls, usually the 208 
unstimulated/untreated samples). Samples with cycling thresholds of 40 in the unstimulated 209 
conditions were not included in the analysis. 210 
Measurement of [Ca
2+
]i in DRG neuron 211 
Mouse DRG neurons were dissociated from whole DRGs as previously described 212 
(Rajasekhar et al., 2015) and plated onto coverslips coated with poly-L-lysine and 100 g/ml 213 
laminin. The DRG neurons were maintained in DMEM containing antibiotic-antimitotic, 214 
10% FBS, and N-1 supplement at 37°C (5% CO2/95% O2) for 24 hours. The DRG neurons 215 
were loaded with Fura-2/AM ester (5μM, 45 min, 37 C) in calcium assay buffer (10 mM 216 
HEPES, 0.5% BSA, 10 mM D-glucose, 2.2 mM CaCl2·6H2O, 2.6 mM KCl, 150 mM NaCl) 217 
containing 4 mM probenecid and 0.05% pluronic F127. Cells were washed and incubated in 218 
calcium assay buffer for 30 min before imaging. Cells were observed using a Leica DMI-219 
6000B microscope with an HC PLAN APO 0.4 numerical aperture X 10 objective and 220 
maintained at 37° C. Images were collected at 1 second intervals (excitation: 340 nm/380 nm; 221 
emission: 530 nm). Cells were challenged sequentially with vehicle, GM-CSF (200 ng/ml), 222 
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capsaicin (0.5 μM; TRPV1 agonist). 50mM KCl, in calcium assay buffer containing 223 
probenecid, was applied at the end of the experiment to obtain maximal [Ca
2+]
i.  224 
Results are expressed as the 340/380 nm fluorescence emission ratio, which is proportional to 225 
changes in [Ca
2+
]i. Data are presented as F/F0, where F is the measured fluorescence 226 
intensity and F0 is the basal fluorescence. All F/F0 values have been subtracted by 1. In each 227 
experiment two technical replicates were included with 68 – 559 neurons recorded in each 228 
repeat. The experiment was repeated three times (n=3) with equivalent results. A response 229 
was deemed positive if it was >10% above baseline. Results were excluded from the analysis 230 
if they showed a fluctuating calcium response prior to addition of GM-CSF or did not show 231 
pronounced reversibility (>50%) from the peak response to GM-CSF application and did not 232 
respond to KCL addition. This constituted <1% of DRG neurons studied.   233 
Detection of ERK1/2 and STAT5 activation in neurons stimulated with GM-CSF  234 
The dissociated DRG neurons plated onto coverslips, as described above for measurement of 235 
[Ca
2+
] (Rajasekhar et al., 2015), were also used for the detection of ERK1/2 and STAT5 236 
activation following GM-CSF stimulation. Following a 24 hour culture in DMEM containing 237 
antibiotic-antimitotic, 10% FBS, and N-1 supplement at 37°C (5% CO2/95% O2), the neurons 238 
were serum-starved overnight (17-18h) by incubating them in DMEM supplemented with 239 
0.1% (w/v) BSA, 100 U/ml penicillin, 100 mg/ml streptomycin, and 1% (v/v) N1 in a 240 
humified incubator at 37° C (95% O2, 5% for CO2). Subsequently, neurons were stimulated 241 
for 15 min with PBS, GM-CSF (200 ng/ml) or PMA (2 µM, Sigma). Cells were then washed 242 
in ice-cold PBS and fixed in 4% paraformaldehyde in PBS for 20 min at room temperature. 243 
After 3 washes with PBS, cells were blocked and permeabilized by incubating with PBS 244 
supplemented with 0.01% Triton-X, 5% heat-inactivated FBS, and 5% goat serum for 60 245 
min. Neurons were washed (3 x PBS), then stained overnight with mouse anti-mouse NeuN 246 
mAb (clone A60) (Millipore) in combination with either rabbit anti-mouse phospho-p44/42 247 
MAPK (Erk1/2) (Thr202/Tyr204) (197G2) mAb (Cell Signaling Technology) or rabbit anti-248 
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mouse phospho-STAT5 (Y694) (D47E7) XP® mAb (Cell Signaling Technology); all 249 
primary antibodies were diluted in PBS with 5% FBS and 0.01% Triton-X. Following 250 
washing (3 x PBS), neurons were incubated with goat anti-rabbit IgG (H+L) antibody, Alexa 251 
Fluor®568 conjugate (ThermoFisher) and goat anti-mouse IgG (H+L) antibody, Alexa 252 
Fluor®488 conjugate (ThermoFisher). Neurons were washed (3 x PBS), then stained with 253 
DAPI (1 µg/ml, 5 min; EMD Millipore). In all experiments, secondary antibody only and 254 
single primary antibody controls were included in order to check for nonspecific secondary 255 
binding and bleed-through of fluorochromes, respectively.   256 
Images were obtained with a Zeiss Axioskop 2 at 10X magnification and  captured by a Zeiss 257 
AxioCam MRm. Each condition included two technical replicates and 5 images were taken 258 
from each replicate. Quantification of positive cells was performed with ImageJ software. For 259 
neurons, only NeuN positive cells were included in the analysis. To determine when cells 260 
were positive a lower threshold for staining intensity in the green channel (Alexa Fluor 488) 261 
was set based on the PBS-treated control cells. Cells with fluorescence intensities above this 262 
threshold were regarded as positive. A mean of positive cells across the 10 images from each 263 
condition was calculated. Three separate experiments were performed. 264 
GM-CSF-induced inflammatory pain 265 
Inflammatory pain was induced by a single intraplantar (i.pl.) injection (10 μl) of GM-CSF 266 
(50 ng/paw, R&D Systems) into the left hind footpad (Achuthan et al., 2016; Cook et al., 267 
2018). 268 
mBSA/GM-CSF-induced arthritis 269 
Monoarticular arthritis was induced by an intraarticular injection of methylated BSA (mBSA) 270 
(100 g in 10 l) into the right knee on day 0, and saline into the left knee, followed by a s.c. 271 
injection of GM-CSF (600 ng) into the scruff of the neck on days 0-2, as before (Achuthan et 272 
al., 2016; Cook et al., 2018). Mice were sacrificed (day 7) and knee joints were removed, 273 
fixed, decalcified and paraffin embedded (Achuthan et al., 2016; Cook et al., 2018). Frontal 274 
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sections (7 m) were stained with H&E and cellular infiltration, synovitis, pannus formation, 275 
cartilage damage and bone erosions were each scored separately from 0 (normal) to 5 276 
(severe) as described previously (Achuthan et al., 2016; Cook et al., 2018); these scores were 277 
then added to give the total histologic score for each mouse.  278 
Assessment of pain-related behaviours  279 
As an indicator of pain, the differential weight distribution over a 3 second period between 280 
the inflamed paw or limb relative to the non-inflamed paw or limb was measured using the 281 
incapacitance meter (IITC Life Science Inc). This technique has been validated for 282 
measurement of both paw and arthritic knee pain (Achuthan et al., 2016; Cook et al., 2018). 283 
Mice were acclimatised to the incapacitance meter on at least 3 separate days prior to the 284 
commencement of the experiment. Three measurements were taken for each time point and 285 
averaged. 286 
Experimental Design and Statistical Analysis 287 
All data are expressed as mean ± SEM, except where stated as median. Statistical analyses 288 
were performed using SPSS (IBM version 23). Kruskal-Wallis non-parametric independent 289 
samples tests were used for analysis of Figures 1, 3 and 4. The samples were corrected for 290 
multiple testing using the Bonferroni correction. For calcium imaging in Figure 2, GM-CSF 291 
activation of neurons and histology, a one-way ANOVA was used, and for pain readings, a 292 
two-way ANOVA was used, with either a Bonferroni or Tukey post-hoc test. A p-value less 293 
than 0.05 was considered significantly different to the null hypothesis of no difference at the 294 
95% confidence level. 295 
 296 
 297 
 298 
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 299 
3. RESULTS 300 
The literature around the involvement of GM-CSF in chronic and neuropathic pain remains 301 
sparse. However, even within this limited literature there is little consensus on the possible 302 
mechanisms behind the actions of GM-CSF in pain. To clarify, we have undertaken a number 303 
of experiments, as follows: 304 
3.1 GM-CSF does not modulate gene expression in purified neurons from mouse DRG 305 
Previous studies have reported that GM-CSF can act directly on nociceptive neurons, and as a 306 
result, cause hyperalgesia (Schweizerhof et al., 2009; Parajuli et al., 2012). Here, we began 307 
by addressing the discrepancy in the literature on the mode of action of GM-CSF by using 308 
Magnetically-Activated Cell Sorting (MACS) to enrich for small and medium diameter 309 
neurons (which are nearly all nociceptors) from mouse DRG. Thakur et al. (2014) showed 310 
that dissociated DRG preparations that are commonly used for analysis actually contain 311 
predominantly non-neuronal cells. In contrast, they showed, that following MACS isolation, 312 
a culture of 95% pure nociceptors can be produced from adult mouse DRG. Large diameter 313 
neurons (>30µm), which are lost during MACS, are largely non-nociceptive (Dubin and 314 
Patapoutian, 2010) and hence their absence is an asset rather than a disadvantage when 315 
studying the role of GM-CSF is nociception and peripheral sensitization.  316 
Parallel cultures of cells from adult mouse DRG were set up using either the traditional 317 
dissociation technique to prepare the mixed (i.e. unsorted) cultures and purified cultures (i.e. 318 
sorted) from adult mouse DRG obtained after MACS. For these sets of experiments, 48 genes 319 
that are known to be expressed in the DRG, including some internal housekeeping controls 320 
(GAPDH, 18S and YWhAZ), were developed into a Taqman qPCR array card 321 
(Thermofisher). This card was used as a screening tool to help provide an indication towards 322 
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specific pathways or areas of interest to be investigated further. The list of genes present on 323 
the card is provided in Table 1A.  324 
Figure 1(A) is a heatmap that shows the gene expression changes in mixed DRG cultures and 325 
pure neurons following GM-CSF and NGF treatment in the panel tested. It is evident that 326 
GM-CSF had an overall greater impact in mixed cultures as compared to pure neuronal 327 
cultures. Only 6% of the genes (n=2/34, namely CSF2RA and IL6) showing a greater than 2-328 
fold average increase in expression level following GM-CSF treatment in the purified 329 
neuronal cultures and none of the differences reached statistical significance.  330 
However, when GM-CSF was applied to the mixed DRG cultures, 44% of the genes 331 
(n=15/34) showed a 2-fold or more average increase in gene expression, and four of these 332 
were found to reach statistical significance with an average increase in expression of 2.3-fold. 333 
Figure 1B shows the significantly altered genes (black dots) along with those showing a 334 
greater than 2-fold increase in expression. The overall average increase in gene expression in 335 
the mixed cultures with GM-CSF stimulation was 3.9-fold, whereas purified cultures 336 
following GM-CSF stimulation showed an average of 1.6-fold increase.  337 
As a positive control, we applied NGF instead of GM-CSF to the mixed and purified cultures 338 
and found, as expected, a significantly increased expression of 12 and 5 genes, respectively. 339 
50% of the genes showed a 2-fold or greater average increase in expression in the mixed 340 
DRG cultures, whereas around 32% of the genes in purified cultures showed a 2-fold or more 341 
average increase in expression. The average fold increase of the significant genes was 5.8 and 342 
2.5 fold in the mixed and purified cell cultures, respectively (data not shown). 343 
These results suggest that GM-CSF is incapable of driving direct transcriptional changes in 344 
neuronal genes in nociceptors. However, changes in neuronal genes in the mixed cultures 345 
following GM-CSF treatment indicate that it might be having an indirect effect on 346 
nociceptors via satellite cells or other non-neuronal cell types that make up the majority of 347 
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the cells in the DRG, and indeed in the mixed DRG cultures. In order to obtain supporting 348 
evidence for the proposal that GM-CSF is incapable of directly stimulating nociceptor 349 
transcription, we reviewed recent publications that have made use of RNA sequencing to 350 
examine gene expression in mouse and human DRG (Table 2, Thakur et al., 2014; Lopes et 351 
al., 2017; Zeisel et al., 2018; Flegel et al., 2015; Ray et al., 2018; Ray et al., 2019). The Table 352 
compares the expression of the two GM-CSF receptor chains to several control transcripts: 353 
Calca, one of the most highly expressed genes in DRG; TrpV1 and Nav1.8, which are well 354 
expressed in nociceptive neurons; and Dnmt3a, which is very lowly expressed (Saunders et 355 
al, 2018). It is evident the two transcripts coding for the receptor chains of the GM-CSF 356 
receptor, namely CSF2Rα and CSF2Rβ, are expressed at levels below our negative control 357 
transcript in the DRG - the CSF2Rβ gene, in particular, appears to be undetectable, even by a 358 
technique as sensitive as RNA-seq. In whole human tibial nerve, mRNA for both receptors 359 
can be detected at higher levels, presumably due to a contribution from non-neuronal cells 360 
(Ray et al., 2019). 361 
3.2 GM-CSF does not directly activate neurons in vitro and in vivo 362 
To support the above gene expression data, suggesting an indirect effect of GM-CSF on 363 
neurons, we monitored some signalling pathways in cultured DRG neurons. We were unable 364 
to observe any GM-CSF-stimulated elevation in intracellular Ca
2+
 levels (Figure 2A and B) 365 
or ERK1/2 phosphorylation (Figure 2C) when compared to our positive controls, namely 366 
capsaicin and PMA, respectively. We were also unable to detect STAT5 phosphorylation 367 
following GM-CSF stimulation in these neurons, unlike in murine macrophages grown from 368 
bone marrow cells in GM-CSF (Fleetwood et al, 2007) (data not shown).   369 
Table 2B indicates that Nav1.8
+
 neurons do not express the Csf2rb gene and therefore cannot 370 
express a functional GM-CSFR. In order to demonstrate in vivo that GM-CSF-induced pain 371 
development is not due to GM-CSF receptor signalling via Nav1.8
+
 neuronal cells (that is, the 372 
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majority of nociceptors), Nav1.8-cre Csf2rb
fl/fl
 mice were generated by crossing the Csf2rb
fl/fl
 373 
mouse (Croxford et al., 2015) with the Nav1.8-cre mouse (Stirling et al., 2005) - these mice 374 
will lack any functional GM-CSF receptors that may possibility be expressed in Nav1.8
+
 375 
neurons. GM-CSF-induced inflammatory pain and GM-CSF-induced arthritic pain were then 376 
initiated, and pain development measured by a change in weight distribution (using the well-377 
validated incapacitance meter method (Achuthan et al., 2016; Cook et al, 2018)). Following 378 
intraplantar injection of GM-CSF, pain was evident in Csf2rb
fl/fl 
control and also in Nav1.8-379 
cre Csf2rb
fl/fl 
mice (Figure 2D). Similarly, following induction of mBSA/GM-CSF arthritis, 380 
similar pain development was evident in WT, Csf2rb
fl/fl 
control and Nav1.8-cre Csf2rb
fl/fl 
381 
mice from day 3 onwards (Figure 2E); all three strains developed a similar degree of arthritis 382 
(at day 7, as judged by histology) (Figure 2E). Taken together, these in vitro and in vivo data 383 
do not support a direct action of GM-CSF on neurons consistent with a lack of GM-CSF 384 
receptor gene expression in neurons. 385 
3.3 Nociceptor gene expression can be indirectly modulated by GM-CSF stimulated 386 
BMDMs  387 
As mentioned, based on the above data, we hypothesised that GM-CSF might be having an 388 
indirect effect on nociceptors via non-neuronal cells that are present within the DRG and in 389 
the periphery at a site of injury. Macrophages are one cell type present in the DRG and 390 
known to be responsive to GM-CSF as well as being a potential source of pain mediators 391 
(Cook et al., 2018, Hore and Denk, 2019). To look for potential indirect effects of GM-CSF, 392 
supernatants from GM-CSF-stimulated BMDM cultures were added to sorted neuronal 393 
cultures to test whether these BMDMs are capable of producing mediators which can elicit 394 
transcriptional changes in neurons. Since our overall aim was to look at the mechanism of 395 
GM-CSF action in pain, a second Taqman card containing probe sets for genes that are 396 
known to be involved in axotomy and pain-related behaviour was used (Table 1B).  397 
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Once again, direct treatment of purified nociceptors with GM-CSF did not cause any 398 
significant dysregulation in the genes present on this array card (Figure 3).  Conditioning 399 
medium from unstimulated BMDMs had no significant impact on neuronal gene transcription 400 
(data not shown). Following treatment with conditioning medium from GM-CSF treated 401 
BMDMs, 31% of the genes tested showed 2-fold or more average increase in gene 402 
expression, calculated by normalizing the transcriptional changes to neuronal cultures that 403 
received supernatants from unstimulated BMDMs. Six genes were found to be significantly 404 
dysregulated following indirect stimulation with GM-CSF. These were ADAM8 (3-fold 405 
increase), ANXA1 (5-fold increase), IL6 (3.5-fold increase), PRDM12 (0.5-fold decrease), 406 
CSF-1 (2.4-fold increase) and JAK2 (2.6-fold increase). In addition to the genes that reached 407 
statistical significance, there were several other changes in known pain-related genes, such as 408 
TNFSF12 (3.6-fold increase), USP18 (5-fold), GAL (2.9 fold), NGF (2.4 fold) and NPY (2.4 409 
fold), which showed increased expression following indirect activation using GM-CSF 410 
treated conditioning medium, but which did not reach statistical significance (Figure 3). 411 
3.4 Macrophage gene expression can be indirectly modulated by NGF stimulated 412 
nociceptors  413 
We investigated next the possibility of cross-talk between stimulated nociceptors and 414 
macrophages. While there is growing evidence to support the view that stimulated immune 415 
cells can communicate with neurons (Marchand et al., 2005; Scholz and Woolf, 2007; 416 
Watkins and Maier, 2002; Sorge et al, 2015, Hore and Denk, 2019), which is supported by 417 
the data in Figure 3, the literature on the ability of stimulated neurons to communicate with 418 
immune cells is more limited (McMahon, LaRussa and Bennett, 2015). To examine this 419 
possibility, we used a similar strategy to that used in Figure 3 to explore whether nociceptors 420 
that had been treated with NGF were capable of producing mediators that could modulate 421 
macrophage gene expression. A third Taqman card containing 48 genes, of which 29 genes 422 
  18 
are known to be expressed in macrophages at levels which depend on their functional state 423 
(Murray et al., 2014), was used.  (Table 1C).  424 
As positive controls, we found that GM-CSF (Figure 4A) and LPS (Figure 4B) stimulation of 425 
BMDMs, as expected, had large impacts on gene transcription. GM-CSF treatment led to 426 
55% of the genes having a 2-fold or more increase in expression; out of these, 9 were found 427 
to be statistically significant after correcting for multiple testing. They were Ccl17, Ccl22, 428 
Ccr2, Il4ra, Irf4, Nfil3, Socs1, Socs2 and Socs3 (Figure 4A). Additionally, cytokine genes 429 
such as Il6, Il1b and Il27 were also found to be upregulated, although without reaching 430 
statistical significance. Stimulation of BMDMs with LPS led to 72% of the genes having a 2-431 
fold or more increase in expression and, out of these, six reached statistical significance, 432 
namely, Ccl17, Fcgr1, Il1b, Il6, Socs1 and Socs3 (Figure 4B).  433 
Conditioning medium from unstimulated neurons had no impact on BMDM gene 434 
transcription (data not shown). Conditioning medium from NGF treated nociceptors caused a 435 
2-fold or more increase in 69% of the genes. Although only four genes reached statistical 436 
significance, namely CCR2, IL4Ra, IRF4 and SOCS2 (Figure 4C). There were several other 437 
genes, namely CCL22, IL1b, IL6, SOCS1 and SOCS3, that showed a trend towards increased 438 
expression following treatment with NGF-stimulated conditioning medium (Figure 4C). It 439 
should be noted that BMDMs do not express the receptors for NGF (TRKA and p75) (e.g. see 440 
RNA-seq data in Ostuni et al, 2013; Piccolo et al., 2017; Hill et al., 2018), demonstrating that 441 
NGF stimulated neurons can produce mediators capable of activating macrophages.  442 
 443 
 444 
 445 
 446 
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 447 
 448 
4. DISCUSSION AND CONCLUSION 449 
In this present study we provide evidence that GM-CSF does not directly activate nociceptors 450 
but suggest that GM-CSF acts through macrophages to produce mediators which interact with 451 
nociceptors. We provide evidence for a bi-directional cross-talk between neurons and 452 
macrophages.  453 
Previous studies have suggested that GM-CSF can act on and stimulate sensory neurons. Bali 454 
et al. (2013) suggested that GM-CSF brought about transcriptional regulation of several pain 455 
genes in sensory neurons in a model of cancer pain, an observation replicated by 456 
Schweizerhof et al. (2009) and Zhang et al. (2019). Donatien et al., 2018 report that GM-CSF 457 
can enhance capsaicin-induced calcium influx in DRG neurons, although not directly induce 458 
calcium influx. However, these studies did not separate neuronal cells from non-neuronal 459 
cells within the DRG and hence it is difficult to attribute these changes specifically to sensory 460 
neurons. In contrast, other recent publications (Lopes et al., 2017; Zeisel et al., 2018) making 461 
use of RNA-sequencing to look for transcriptional changes in a cell-specific manner have 462 
indicated the absence of the GM-CSFR chain on nociceptors, indicating alternate 463 
mechanisms of action. In this context, a TrkA inhibitor was able to reduce the GM-CSF 464 
enhanced capsaicin-induced calcium influx response, suggesting GM-CSF may be acting 465 
indirectly via NGF (Donatien et al., 2018).  466 
Therefore, we looked for changes caused by stimulating purified nociceptors with GM-CSF 467 
and found no significant transcriptional changes. Also, even if there was some expression of 468 
the GM-CSF receptor on neurons, deleting the Csf2rβ subunit in Nav1.8+ neurons (i.e. most 469 
nociceptors) in vivo showed no effect on the generation of GM-CSF-driven inflammatory and 470 
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arthritic pain, suggesting that GM-CSF does not act directly via nociceptors. It has been 471 
reported that low and high threshold A fibres respond to GM-CSF (Schweizerhof, 2009). 472 
Based on our findings, we consider that these responses are possibly indirect although 473 
further studies are needed to address this issue. Overall, our results lead us to hypothesise 474 
that the reported effects of GM-CSF on DRGs (Bali et al., 2013; Schweizerhof 2009) were 475 
predominantly due to the ability of GM-CSF to activate non-neuronal cells associated with 476 
nociceptors, likely in the peripheral nerve itself or during myeloid cell infiltration into the 477 
DRG. These non-neuronal cells might then indirectly bring about transcriptional changes in 478 
nociceptors associated with pain/hyperalgesia.  479 
Macrophages are one of the most commonly studied cell type in the pain field due to their 480 
involvement in the pathogenesis of various neuropathies (Lu and Richardson, 1993). Zhang et 481 
al. (2016) showed that recruitment of macrophages to the DRG was important for inducing 482 
and maintaining chemotherapy-induced peripheral neuropathy, an observation in accordance 483 
with several other studies showing increased myeloid cells in the DRG following peripheral 484 
injury (Hu and McLachlan, 2002; Fenzi et al., 2001). Furthermore, Shepherd et al. (2018) 485 
showed that the angiotensin II receptor (AT2R) antagonist reduces neuropathic pain by 486 
blocking the downstream signalling of AT2R in infiltrating peripheral macrophages, as 487 
sensory neurons lack expression of this receptor. Blocking of macrophage activation using 488 
TLR antagonists (Jurga et al., 2018) and inhibitors of p38 MAPK/MMP9 (Hutchinson et al., 489 
2008; Mika et al., 2007), PI3K and NF-kB (Popiolek-Barczyk et al., 2015) has analgesic 490 
effects in various models of neuropathic pain, consistent with our proposed mechanism of 491 
action.  492 
We therefore analysed whether factors from stimulated macrophages can bring about 493 
transcriptional changes in nociceptors that mimic injured or activated nociceptors. We found 494 
that supernatants from GM-CSF stimulated macrophages upregulated several neuronal genes, 495 
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namely ADAM8, ANXA1, IL6, CSF-1 and JAK2, which are also significantly upregulated 496 
following injury (Chen et al., 2014; Pei et al., 2011; Tang et al., 2018; Guan et al., 2016; Ding 497 
et al., 2018; Diaz-DelCastillo et al., 2018). Supernatants from GM-CSF stimulated 498 
macrophages were found to significantly down-regulate expression of PRDM12, an 499 
important nociceptor gene (Desiderio et al., 2019). There is evidence to suggest that, 500 
following injury, activated monocytes from the spleen and lymph nodes infiltrate into the site 501 
of injury as well as the associated DRG (Hu and McLachlan, 2002; Schmid et al., 2013). It is 502 
expected that inflammatory cytokines from these immune cells can then impact the neurons 503 
by affecting their firing rates and causing changes in gene expression (Ozaktay et al., 2006; 504 
Ohtori et al., 2004).  505 
Of the mediators that were upregulated in our experimental set up, CSF1 was of particular 506 
interest from the perspective of nerve injury. The role of microglia in chronic pain is well 507 
established, with various proposed mechanisms to drive microglial activation and central 508 
sensitisation in a variety of pains states (Calvo and Bennett, 2012; Denk et al., 2016; 509 
Fernandez-Zafra et al., 2018). It has been demonstrated that peripheral nerve injury induces 510 
the production of CSF-1 in neurons, which then recruit spinal cord microglia to proliferate 511 
(Guan et al., 2016). The presence of large numbers of activated microglia is responsible for 512 
further activation of spinal neurons and maintenance of neuropathic pain through the release 513 
of inflammatory and neuropathic mediators (Kawasaki et al., 2008, Zhao et al., 2017). The 514 
release of CSF-1 from nociceptors raises the possibility of bi-directional cross-talk with 515 
nociceptors further recruiting and stimulating macrophages in a positive feedback loop. 516 
Therefore, we looked for transcriptional changes in macrophages following treatment with 517 
conditioning media from stimulated neurons. 518 
Analysis of macrophages at a site of nerve injury has shown them to be predominantly anti-519 
inflammatory in nature and involved in regeneration and recovery of the nerve (Ydens et al., 520 
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2012; Gaudet, Popovich and Ramer, 2011). Interestingly, macrophages stimulated with 521 
supernatants from NGF treated neurons led to an upregulation of cytokine and chemokine 522 
receptors (IL4Ra and CCR2) and transcription factors (SOCS2 and IRF4). Since NGF by 523 
itself is incapable of directly activating macrophages (Ostuni et al., 2013; Piccolo et al., 2017; 524 
Hill et al., 2018), it can be assumed that the transcriptional changes in macrophages were due 525 
to mediators being released by these stimulated nociceptors (Vega et al., 2003). Furthermore, 526 
these transcriptional changes were distinct from those following direct stimulation with LPS 527 
or GM-CSF, suggesting a distinct mechanism of action. We found that NGF stimulated 528 
nociceptors upregulate the expression of inflammatory mediators and chemokines, such as 529 
IL-1β, IL6 and CCL22, which have the potential to activate and recruit macrophages.  530 
Here we, like many others, have used in-vitro dissociated DRG cultures to study nociceptive 531 
processes. However, unlike nearly all previous studies, we use highly purified neurons in the 532 
culture. This allows us to disambiguate direct versus indirect effects of applied agents – a key 533 
advantage and main point of this study. The disadvantage being that the cellular properties 534 
inevitably change somewhat over time in culture as seen by transcriptional profiling of such 535 
cultures (Thakur et al., 2014; Lopes et al., 2107; Wangzhou et al., 2019). Some of the 536 
emergent changes suggest that cultured nociceptors take on a ‘neuropathic’ phenotype 537 
(Wangzhou et al., 2019) and so one caveat of the current work is that, inevitably, the neurons 538 
we studied are not in their native state.   539 
One of the problems we faced during these experiments was the intra-group variability 540 
observed in the transcriptional analysis. Variability in transcriptional analysis is a common 541 
phenomenon (Volfson et al, 2006; Raser and O’Shea, 2005) since transcription is not a 542 
continuous process, but rather a discontinuous one that takes place in ‘bursts’ and ‘pulses’. 543 
Hence differences in the expression levels of lowly and highly expressed genes can be 544 
observed even in the absence of any stimulus leading to the observed variability (Chubb and 545 
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Liverpool, 2010). In this study, we have made use of stringent statistical tests in order to 546 
cover the inherent intra-group variability and hence identify transcripts that are genuinely 547 
dysregulated because of the treatments.  548 
It is important to note in this context, that whilst nociceptor transcriptional change is very 549 
common in persistent pain states, nociceptors can be activated and sensitised without 550 
transcriptional change (eg Wu et al., 2001; Zhang and Strong, 2008). But transcriptional 551 
change in nociceptors, when it does occur, can lead to changes in the sensitivity and activity 552 
of these neurons and is thereby an important regulator of nociceptor function. In the current 553 
experiment we looked for acute effects of GM-CSF on calcium signalling in purified 554 
nociceptors but did not observe any of these non-transcriptional actions. Others who have 555 
seen non-transcriptional effects of GM-CSF on cultured neurons have used mixed cultures 556 
containing a variety of cell types which may allow for indirect activation of nociceptors via 557 
non-neuronal cells (Schweizerhof et al., 2009; Bali et al., 2013; Donatien et al., 2018). 558 
Indeed, in those experiments, the non-transcriptional effects of GM-CSF were blocked by 559 
trkA inhibitors, suggesting the release of secondary mediators.  560 
In conclusion, the findings in this study highlight the need to dissect the mechanisms of 561 
action of cytokines at a cell-type specific level, with a view to developing more targeted 562 
therapies and interventions to treat pain. Our findings support the concept that immune cells 563 
and neurons at the site of nerve injury are engaged in a loop that involves cross-talk between 564 
them. More specifically, pro-inflammatory mediators and cytokines released from GM-CSF 565 
stimulated monocytes or macrophages act on neurons which in turn release neurotransmitters 566 
that can further activate these immune cells. The net effect is likely to be peripheral 567 
sensitization and consequent chronic pain.  568 
 569 
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Legends 928 
Table 1: (A) Genes represented on a DRG card. (B) Genes represented on an axotomy card. 929 
(C) Genes represented on a macrophage card. 930 
Figure 1: GM-CSF causes dysregulation of genes in mixed DRG cultures but not in 931 
purified neuronal cultures. (A) Heatmap representing the transcriptional changes in a panel 932 
of genes (see Table 2A) was assessed in mixed DRG cultures and pure MACS sorted 933 
neuronal cultures from C57Bl/6J mice following treatment with GM-CSF (2µg/ml) for 48hrs 934 
and NGF (10ng/ml). Each column represents average data of n=8 independent experiments. 935 
Each individual experiment contained pooled cells from two mice. (B) Genes showing a 2-936 
fold or greater change in expression changes following GM-CSF treatment in unsorted DRG 937 
cell cultures as compared to purified neurons. Each dot represents a separate gene which is an 938 
average of n=8 experiments. Dotted line represents untreated control. Solid line represents 939 
mean of each group. Kruskal-Wallis test was conducted to identify genes that were 940 
significantly modulated after treatment with GM-CSF in mixed DRG cultures (highlighted 941 
black dots). The results were corrected for multiple comparisons using the Bonferroni 942 
correction. None of the genes from purified neuronal cultures reached statistical significance 943 
after GM-CSF treatment. *, adj p<0.05; * = Genes significantly different from untreated 944 
control. +, adj p<0.05 and ++, adj p<0.01; + = Genes significantly different between whole 945 
DRG and purified neurons. 946 
Table 2: Expression values derived from publicly available (A) bulk and (B) single cell 947 
RNA-sequencing datasets. Data for Csf2ra and Csf2rb are provided along with the following 948 
control/comparison genes: Calca, which is one of the most highly expressed genes in DRG; 949 
TrpV1, which is well expressed in nociceptive neurons; Dnmt3a which is very lowly 950 
expressed if at all in neurons (Saunders et al., 2018); Nav1.8; CD40, a myeloid cell marker; 951 
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and Uchl1, the gene coding for a protein which is highly expressed in nerve fibres,. FPKM = 952 
fragments per kilobase per million mapped reads; TPM = transcripts per million.  953 
Figure 2. GM-CSF does not directly activate neurons in vitro and in vivo. (A-B) Time 954 
course and peak Ca
2+
 responses in mixed DRG cultures in response to vehicle, GM-CSF (200 955 
ng/ml), capsaicin (0.5 µM) and KCl (50 mM) (only A), respectively. (A) grey lines, 956 
individual traces from 50 random cells; black lines, mean response; (B) n=1767 neurons 957 
(pooled data from two independent experiments). (C) Percentage of DRG neurons positive 958 
for phospho-ERK1/2 following stimulation with PBS, PMA or GM-CSF (200 ng/ml) for 15 959 
mins. Three independent experiments were performed. (D-E) Pain development 960 
(incapacitance meter – ratio of weight bearing on injected relative to noninjected 961 
knee/hindpaw – a value of  < 100 indicates pain) was measured following (D) intraplanatar 962 
(i.pl.) injection of GM-CSF (20 ng) in Csf2rb
fl/fl 
 and Nav1.8-cre Csf2rb
fl/fl 
mice (n=5-8 963 
mice/group) and (E) mBSA/GM-CSF arthritis (mBSA i.a. [day 0]; GM-CSF or saline s.c. 964 
[days 0-2]) induction in WT, Csf2rb
fl/fl 
 and Nav1.8-cre Csf2rb
fl/fl 
mice (n=4-7 mice/group). 965 
For (E) arthritis (histology, day 7) was also assessed. (C-E) Data is expressed as mean + 966 
SEM. For (B) and (C), a one-way ANOVA was used. *** p<0.001, **** p<0.0001.  967 
Figure 3: Nociceptor gene expression can be indirectly modulated by conditioning 968 
media from GMCSF stimulated BMDMs. Genes dysregulated by 2-fold or more from 969 
nociceptors that received conditioning medium from GM-CSF (2µg/ml) treated BMDMs. 970 
Each dot represents a separate gene which is an average of n=10 individual experiments. 971 
Kruskal-Wallis test was conducted to identify genes that were significantly modulated after 972 
treatment with the conditioning medium (highlighted black dots). The results were corrected 973 
for multiple comparisons using the Bonferroni correction. None of the genes from purified 974 
neuronal cultures that were treated directly with GM-CSF (2µg/ml) reached statistical 975 
significance. Samples with cycling thresholds of 40 in the unstimulated conditions were not 976 
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included in the analysis. Dotted line represents untreated control. Solid line represents mean 977 
of each group. No significant changes were seen with untreated conditioning media control 978 
from BMDMs on neuronal cultures. *, adj p<0.05; * = Genes significantly different from 979 
untreated control. ++, adj p<0.01; + = Genes significantly different between direct GM-CSF 980 
stimulation and conditioning media with GM-CSF. 981 
Figure 4: Macrophage gene expression can be indirectly modulated by NGF stimulated 982 
nociceptors.   BMDMs were treated with (A) GM-CSF, (B) LPS and (C) conditioning 983 
medium from NGF-stimulated nociceptors for 48hrs (Materials and Methods). The fold 984 
change in the expression of dysregulated genes on a macrophage card (Table 1C) is depicted 985 
on a log10 scale. Only significantly dysregulated genes are depicted in (A) and (B). Each dot 986 
represents a separate experiment (n=10). Kruskal-Wallis test was conducted to identify genes 987 
that were significantly modulated after treatment. The results were corrected for multiple 988 
comparisons using the Bonferroni correction. Dotted line represents untreated controls where 989 
conditioning media from untreated nociceptors was applied to BMDMs. No significant 990 
changes were seen in BMDM cultures treated with conditioning medium from untreated 991 
nociceptors as a control. Box and Whisker plots showing maximum to minimum range. 992 
Samples with cycling thresholds of 40 in the unstimulated conditions were not included in the 993 
analysis. *, adj p<0.05 ; **, adj p<0.01 and ***, adj p<0.001. 994 
 995 
 996 
 997 
 998 
 999 
 1000 
  43 
Table 1: Genes probe sets present on qPCR array cards. 1001 
 1002 
Adcyap1 Tac1 
 
Gapdh Sfpq 
 
Arg1 Il4ra 
Atf3 Trpa1 
 
Ywhaz Scn10a 
 
B2m Il6 
Bdnf Trpv1 
 
Hbb Calca 
 
Gapdh Irf4 
Cacna2d1 Gapdh 
 
Fabp7 Hoxb5 
 
Ccl17 Irf5 
Calca Ywhaz 
 
Sox10 Kcnt1 
 
Ccl22 Mertk 
Ccl2 Il6st 
 
CCL21b Scn4a 
 
Ccl24 Mmp9 
Nos1 Ccl4 
 
Csf1 Prdm12 
 
Ccr2 Nfkbiz 
Vgf Il6 
 
Il34 Gamt 
 
Ccr6 Nos2 
Gal Il11 
 
Gap43 Prmt8 
 
Cd19 Ppard 
Gch1 Stat3 
 
Gal Ngf 
 
Fcgr1 Pparg 
18S Tnf 
 
18S Areg 
 
18S Ptgs2 
Ngf Tlr4 
 
Bdnf Il6 
 
Chil3 Retnlb 
Ngfr Il1b 
 
Sema6a Vgf 
 
Cybb Sbno2 
Npy Ccl3 
 
Npy Dpysl5 
 
Foxp3 Socs1 
Ntrk1 Ccl5 
 
Nts Jak2 
 
Gata3 Socs2 
Ntrk2 Cxcl12 
 
Npy2r Srrm4 
 
Gata6 Socs3 
Ntrk3 Il18 
 
Star Camk1 
 
Ido1 Sox10 
Oprm1 Areg 
 
Adam8 Usp18 
 
Ifng Stat1 
P2rx3 Csf1 
 
Casp3 Ntrk1 
 
Il10 Stat6 
P2rx4 Csf3 
 
Atf3 Ucn 
 
Il12a Tbx21 
Il6ra Csf2ra 
 
Cacna2d1 Jun 
 
Il1b Dpysl5 
Scn10a Ccl20 
 
P2rx3 Anxa1 
 
Il22 Tgfb2 
Scn11a Il17a 
 
Kcnmb1 Ngfr 
 
Il27 Tnf 
Scn9a Ereg 
 
Dnm3 Tnfsf12 
 
Il4 Nfil3 
 1003 
 1004 
Table 1: (A) Genes represented on a DRG card. (B) Genes represented on an axotomy card. 1005 
(C) Genes represented on a macrophage card. 1006 
  1007 
(A) (B) (C) 
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 1008 
Table 2: GM-CSF receptor subunit expression in neurons by RNA sequencing.  1009 
 1010 
Single-cell Sequencing of mouse DRG (Zeisel et al; mousebrain.org) - Trinarization Scores 
    Csf2ra Csf2rb Calca TrpV1 Dnmt3a Nav1.8 
Peptidergic (TrpM8), DRG 0.18 0 0.39 2.21 0.36 0 
Peptidergic (TrpM8), DRG 0.27 0 0.32 0.67 0.11 0.08 
Peptidergic (TrpM8), DRG 0.11 0 4.04 0.31 0.22 0 
Peptidergic (PEP1.2), DRG 0.2 0 11.3 3.07 0.1 0.19 
Peptidergic (PEP1.3), DRG 0.13 0 43.4 2.68 0.15 1.56 
Peptidergic (PEP1.1), DRG 0.19 0 37.3 1.02 0.13 1.16 
Peptidergic (PEP1.4), DRG 0.19 0 52.3 3.26 0.32 2.51 
Peptidergic (PEP2), DRG 0.12 0 61.6 0.56 0.24 3.38 
Neurofilament (NF2/3), DRG 0 0 0.64 0 0.19 0.61 
Neurofilament (NF4/5), DRG 0.11 0 0.07 0.05 0.35 0.04 
Neurofilament (NF1), DRG 0.08 0 0.07 0 0.13 0.03 
Non-peptidergic (TH), DRG 0.18 0 0.17 0.01 0.35 1.08 
Non-peptidergic (NP1.1), DRG 0.15 0 6.38 0.06 0.33 3.71 
Non-peptidergic (NP1.2), DRG 0.22 0 3.23 0.05 0.27 5.28 
Non-peptidergic (NP2.1), DRG 0.24 0 11.1 0.04 0.38 5.47 
Non-peptidergic (NP2.2), DRG 0.18 0 34.5 0.73 0.27 4.99 
Non-peptidergic (NP3), DRG 0.26 0 0.74 1.95 0.26 4 
 1011 
 1012 
 1013 
Bulk-sequencing 
  Mouse Tissue Human Tissue 
  Thakur et al. Lopes et al. Lopes et al. Flegel et al. Ray et al. a Ray et al. b 
  
MACS-sorted 
nociceptors 
MACS-sorted 
nociceptors 
after nerve 
injury 
FACS-
sorted 
nociceptors 
whole DRG 
whole 
DRG 
  
human tibial 
nerve 
Expression 
Units: 
FPKM FPKM FPKM FPKM TPM 
  
TPM 
Csf2ra 4 3 2 0 0 CSF2RA 15 
Csf2rb 1 0 0 1 1 CSF2RB 6 
Calca 912 3987 10287 313 1701 CD40 49 
TrpV1 58 154 112 48 73 TRPV1 7 
Dnmt3a 4 2 2 5 4 UCHL1 92 
(A) 
(B) 
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 1014 
Table 2: Expression values derived from publicly available (A) bulk and (B) single cell 1015 
RNA-sequencing datasets. Data for Csf2ra and Csf2rb are provided along with the following 1016 
control/comparison genes: Calca, which is one of the most highly expressed genes in DRG; 1017 
TrpV1, which is well expressed in nociceptive neurons; Dnmt3a which is very lowly 1018 
expressed if at all in neurons (Saunders et al., 2018); Nav1.8; CD40, a myeloid cell marker; 1019 
and Uchl1, the gene coding for a protein which is highly expressed in nerve fibres,. FPKM = 1020 
fragments per kilobase per million mapped reads; TPM = transcripts per million.  1021 
 1022 
 1023 




